The embedding problem is the whole problem
Mohs micrographic surgery is usually described as a surgical technique. It is more accurately a laboratory technique with a surgical front end. The cure rates that justify the procedure — 98% to 99% for primary non-melanoma skin cancer — depend entirely on whether the tissue on the slide faithfully represents the entire peripheral and deep margin of what was removed. When Mohs fails, it usually fails between the chuck and the coverslip.
At a glance: section target 4–6 µm · skin cutting range −25 to −30 °C · cartilage −16 to −22 °C · epidermal margin target 95% · rapid MART-1 15–20 min
Every other technical concern in a Mohs lab is downstream of one question: are the epidermal edge, the lateral margin, and the deep margin all in a single flat plane before the first section is cut?
When they are not, the histotech faces an unwinnable trade. Cut deeper to bring the full circumference into the plane of section, and you consume the margin you were asked to evaluate. Stop early, and you hand the surgeon a slide with a gap in the epidermal edge — the exact location where residual tumor is most likely to hide.
The magnitude is measurable. A comparison of three tissue preparation methods reported in Virchows Archiv found that with a conventional chuck, specimens required an average of 304 µm of sectioning before the deep margin was cleared, and four out of five specimens still did not contain 95% of the epidermal margin. A purpose-built flattening device reduced that to roughly 104 µm while achieving 95% epidermal margin representation.2 That is hundreds of microns of tissue discarded before the diagnostic surface is even reached — on a specimen where the entire point is complete margin control.
This is also why “tissue drop-out” and “missing epidermal or dermal tissue” appear so reliably in recurrence audits, rather than in conversations about surgical skill. The surgeon excised the tumor correctly. The slide simply never showed the place where it remained.
Practical takeaway: Treat flattening as a measured step, not a feel. If your techs routinely face more than 100–150 µm into a specimen to get a complete first section, the problem is the embedding method, not the operator.
2. Temperature is not a single setting
A cryostat set once and left there is a standing source of artifact, because different tissues fail in opposite directions.1
| Condition | Setting | What you see |
|---|---|---|
| Skin, working range | −25 / −30 °C | Clean ribbons |
| Too cold | below range | Nicks, tears, whole regions “chunking” away |
| Too warm | above range | Accordion folding — compression ripples that stack tissue on itself |
| Adipose | colder | Needs longer freeze times and a deliberately thicker section |
| Cartilage | −16 / −22 °C | Shatters when very cold; keep moisture and perichondrium |
Freeze rate matters separately from freeze temperature. Slow freezing at very low temperature produces the classic ice-crystal artifact, in which nuclear detail disappears into a lattice of holes. The fix is rapid freezing — heat sink, isopentane bath, or controlled spray — not the temperature dial.
3. Section thickness and blade condition
Epithelial cells are roughly 8 µm thick, which sets the window. 4–6 µm is the working target.1
- At roughly 12 µm, sections read dark and muddy; overlapping nuclei obscure the detail that separates tumor from follicular structures.
- At roughly 3 µm, sections are faint, difficult to interpret, and prone to chunking.
Both extremes generate interpretive error, not merely cosmetic complaints. In the published concordance data, the most common category of disagreement between Mohs surgeons and dermatopathologists was the false positive — sections read as tumor that were not — attributed largely to thick sections and inflammation being over-read as malignancy.4 Thick sections do not just look bad. They generate additional stages.
Dull blades belong in the same category. A damaged edge produces tears that are, at a glance, indistinguishable from real tissue defects.
4. Staining failures that imitate pathology
Staining problems are under-discussed relative to how often they change a read:1
- Skipped or weak hematoxylin renders a slide functionally uninterpretable.
- Skipped eosin collapses tissue differentiation, though architecture survives.
- Inadequate 100% alcohol dehydration leaves water beads or haze across the section.
- Insufficient or incompatible clearing agent produces bubbles and coverslip lift.
One documented example is worth knowing because the cause is non-obvious: an “incomplete staining artifact” traced to an interaction between acetone and the hematoxylin solution, producing patchy under-staining that mimicked tissue loss. The reported fix was a 15-second water rinse inserted between the acetone and hematoxylin steps — a protocol change, not a reagent replacement.6
Practical takeaway: When a staining defect appears suddenly across many slides, examine sequence and carryover before blaming the reagent lot.
5. The errors that never appear on the slide
A perfectly cut, perfectly stained section is useless if it is mapped to the wrong place. Documented sources of error in Mohs mapping include incorrect orientation, inking errors, miscommunication between surgeon and histotech, and specimen mislabeling at the cryostat — and the probability of each rises with case volume and stage count.3
These produce both false negatives and false positives, and unlike artifact, they leave no visible trace for the reviewing surgeon to catch.
The counterweight is reassuring. Across nine studies and 11,190 slides, concordance between Mohs surgeons and dermatopathologists ranged from 94.90% to 99.79%, highest among fellowship-trained surgeons in academic settings. Interpretation is not the weak link. Among the small number of discordant cases, roughly 49% were false positives, 41% were false negatives, and 8% involved melanoma in situ missed on frozen section.4
Recurrence audits point the same direction. In a case-control review of recurrent tumors, findings associated with recurrence were dense inflammation at the final margin where tumor had been present on prior slides (27%), visible remaining tumor (23%), missing epidermal or dermal tissue (23%), and actinic keratosis (4%) — with surgeon error, tissue drop-out, aggressive subtype, and cases requiring three or more stages emerging as significant factors.5
Nearly all of those are lab-side or communication-side, not diagnostic-skill-side.
6. When H&E is not enough
Melanocytic lesions remain the honest limitation of routine frozen section. Rapid MART-1 protocols have compressed immunostaining to 15 to 20 minutes, with frozen-section results reported as equivalent to MART-1 on permanent sections — a meaningful improvement in both accuracy and chair time.78
Keep in front of you: MART-1 does not stain purely desmoplastic melanoma. Where desmoplastic disease is suspected, deferring reconstruction pending permanent sections with S100 or SOX-10 is the defensible course.
7. The pressures that are not histology at all
Three external forces are shaping Mohs labs right now, and they belong in the same conversation.
Staffing. The histology vacancy rate reported in ASCP’s vacancy survey was 8.37%, up from 5.6% in the prior cycle, with 18.24% of histology supervisors expected to retire within three to five years. The National Society for Histotechnology attributes the gap to an insufficient education pipeline, wages that have barely tracked inflation, and pandemic-era attrition.9 Mohs histotechnology draws from a narrower pool still, and much of the skill transfers by apprenticeship rather than formal curriculum. Practically: technique that lives only in one person’s hands is an operational risk.
CLIA lab director qualifications. A CLIA revision effective December 28, 2024 removed American Board of Dermatology certification as a standalone qualifying credential for directing a high-complexity laboratory — the category Mohs histopathology falls into. Following AADA advocacy, CMS announced it will not enforce the provisions excluding board-certified dermatologists.1011 The precision matters: this is enforcement discretion, not a rewritten rule. Labs that restructured directorship in response should document the current CMS position in their compliance file rather than assume the matter is permanently closed.
Reimbursement. Billing analyses of the 2026 Medicare Physician Fee Schedule describe a conversion factor increase — to roughly $33.40, from $32.35 — offset by a 2.5% efficiency adjustment applied to work RVUs on the procedure codes dermatology depends on, with vendor estimates of a net reduction near 12% for CPT 17311 and 8% for 88305.12 Treat those specific percentages as vendor modeling rather than settled fact, and verify against your own MAC’s fee schedule. The direction is not in dispute: per-stage economics are tightening while documentation scrutiny on Mohs increases.
8. A safety note that gets skipped
Mohs labs section fresh, unfixed tissue, which makes the cryostat the highest aerosol-risk station in most histology workflows. Trimming generates micron-scale fragments inside the chamber. Rapid freeze sprays make this materially worse, because the chamber lid must be open to use them — aerosolizing whatever is on the specimen into the room.13
Two rules follow: treat every specimen as potentially infectious, and avoid cryospray entirely when a high-risk pathogen is known or suspected.
Widely misunderstood: Fixation is not disinfection for tissue. It disinfects the slide surface, not the specimen.
The short version
If you audit one thing this quarter, audit how much tissue your lab consumes before it produces a complete first section. That single measurement sits upstream of margin completeness, stage count, chair time, and — per the recurrence data — a meaningful share of the tumors that come back.
Everything else on this list is real, but it is troubleshooting. Embedding is architecture.
A note about sources
Every figure in this article is a paraphrased summary of findings reported in the cited sources. No text, tables, or figures from any source have been reproduced. Quantitative results are restated in our own words for commentary and educational purposes, with full attribution and a direct link to each original so readers can consult it firsthand.
Two items deserve specific attention. The 304 µm and 104 µm figures attributed to Virchows Archiv2 are summarized from the published abstract, which sits behind a publisher paywall; we have not reproduced any portion of the article text, and readers who need to rely on those numbers should obtain the paper directly from Springer. The 2026 reimbursement percentages12 come from a commercial billing vendor’s analysis rather than from CMS, and are presented as vendor modeling, not as an official figure — verify against your own MAC’s published fee schedule before acting on them.
Citations to StatPearls13 and to open-access articles hosted on PubMed Central4 are linked to the freely available versions. If you are a rights holder and believe any characterization here is inaccurate, contact us and we will correct it.
References
Ibrahim M, et al. Mohs Micrographic Surgery Interpretation of Technical Problems Impacting Slide Quality. StatPearls, NCBI Bookshelf. ↩↩↩↩
Kimyai-Asadi A, et al. Tissue preparation for Mohs’ frozen sections: a comparison of three techniques. Virchows Archiv, 2007. Paywalled — abstract only. ↩↩
Mohs Micrographic Surgery Mapping Techniques. StatPearls, NCBI Bookshelf. ↩↩
Concordance rates among dermatopathologists and Mohs surgeons in frozen section Mohs slides: a systematic review. PubMed Central. ↩↩↩
Campbell T, et al. Surgeon error and slide quality during Mohs micrographic surgery: is there a relationship with tumor recurrence? Journal of the American Academy of Dermatology, 2013. ↩
Incomplete Staining Artifact: A Confounding Frozen Section Pathology Artifact Encountered During Mohs Micrographic Surgery. Journal of Drugs in Dermatology, 2022. ↩
Cherpelis BS, et al. The 20-Minute Rapid MART-1 Immunostain for Malignant Melanoma Frozen Sections. Dermatologic Surgery, 2008. ↩
Melanoma Treated With Mohs Micrographic Surgery Using a Novel-Modified 15-Minute MART-1 Immunostain. PubMed, 2020. ↩
Histotech Workforce Shortages. National Society for Histotechnology, citing the ASCP Vacancy Survey. ↩
CMS suspends CLIA lab director enforcement policy. American Academy of Dermatology. ↩
CLIA Lab Director Qualifications Amended to Include ABD-Certified Dermatologists. American Board of Dermatology. ↩
2026 Dermatology Medicare Update. uControl Billing. Vendor analysis. ↩↩
15 Questions and Answers on Safety in the Histopathology Lab. Leica Biosystems Knowledge Pathway. ↩